Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

31/01/2015 Iranian entrepreneurs at the ALBA synchrotron 22/01/2015 What is a synchrotron and how it works? 15/01/2015 AFM2015 at ICMAB: Nanoscale Characterization of Functional Materials 08/01/2015 Ice under investigation: ICN2 and ICMAB sign an agreement with SnowWorld 23/12/2014 Kymos Pharma Services in the PTV 18/12/2014 Barcelona is one of the 20 best cities for students
35 36 37 38 39 40 41 42 43 44 45